Up to 50% of all patients face an intermediate risk of developing CAD, and the optimal treatment strategy for that population remains unclear. For this study, researchers explored data from more than 400 intermediate-risk patients with a family history of premature CAD.

The advanced machine learning model tracks more than 50 different factors to make its predictions. It has already been found to be more accurate than popular prediction methods for heart disease that are currently available. 

Deepak Bhatt, MD, detailed several recent clinical trials that could reshape the way clinicians manage acute coronary syndrome (ACS) patients.

A catheter sheath detached during use and was left in the patient’s body. It was successfully removed, but the FDA said it is now evaluating the potential risk to others going forward. There is no official recall at this time.

Coronary artery disease is both underdiagnosed and undertreated in women, and they often receive less guideline-recommended care than men. Why do these disparities persist? And what can today’s healthcare providers do to bring about change?

Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."

Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.

Researchers focused on data from nearly 78,000 adults with cardiometabolic disorders, sharing their findings at ACC.25 in Chicago.